Minimum manufacturing costs, national prices and estimated global availability of new repurposed therapies for COVID-19

Junzheng Wang, Jacob Levi, Leah Ellis, Andrew Hill
doi: https://doi.org/10.1101/2021.06.01.21258147

Article Information

doi 
https://doi.org/10.1101/2021.06.01.21258147
History 
  • October 18, 2021.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Junzheng Wang*,1,
  2. Jacob Levi*,2,
  3. Leah Ellis1 and
  4. Andrew Hill3,†
  1. 1Faculty of Medicine, Imperial College London
  2. 2Department of Intensive Care, University College London Hospital, University College London Hospitals NHS Foundation Trust
  3. 3Department of Pharmacology and Therapeutics, University of Liverpool
  1. ↵†Corresponding author:
    Dr Andrew Hill PhD, Department of Pharmacology and Therapeutics, University of Liverpool, 70 Pembroke Place, Liverpool L69 3GF, UK, Email: microhaart{at}aol.com

  1. ↵* JW and JL contributed equally to this manuscript.

Back to top
Posted October 18, 2021.
Download PDF
Data/Code
Email
Minimum manufacturing costs, national prices and estimated global availability of new repurposed therapies for COVID-19
Junzheng Wang, Jacob Levi, Leah Ellis, Andrew Hill
medRxiv 2021.06.01.21258147; doi: https://doi.org/10.1101/2021.06.01.21258147
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area